In the past trading week (June 17 to 21), US Congress voted in favor of an amendment to prevent the justice department from cracking down on the marijuana industry using federal funds.

A report on the potential value of the marijuana industry by 2024 made headlines, while numbers on tax revenue seen since the legalization of recreational products in Canada also caught attention.


Here’s a closer look at some of the biggest news during last week’s trading period.

US Congress vote

The US marijuana industry gained a new layer of protection thanks to the passing of a measure to prevent any obstruction from the Department of Justice on legal cannabis programs at the state level.

The amendment approved by the US House of Representatives will be attached to the 2020 fiscal year Commerce-Justice-Science spending bill. Because of the policy, the federal agency won’t be allowed to use any funds for the criminal pursuit of marijuana programs in medically and recreationally legal states.

According to a report from MJBiz Daily on Thursday (June 20), the vote was approved 267 to 165.

New projections on marijuana market value

On Thursday, Arcview Market Research and BDS Analytics indicated that, thanks to growth seen industry wide in 2018, global legal cannabis sales are now projected at US$40 billion by 2024.

“A key takeaway from the report is that highly restrictive regulations and high tax rates are hurting the legal market’s ability to compete with the illicit market,” Tom Adams, managing director and principal analyst for BDS Analytics’ industry intelligence group, said in a press release. “But legalization advocates endorsed our view that all 50 US states can be expected to be medically legal by 2024, and that 20 will have adult-use sales.”

The Canadian recreational cannabis market is expected to grow to US$4.8 million by 2024.

“Investment capital raised by cannabis companies more than quadrupled to US$14 billion in 2018, according to Viridian Capital Advisors,” the research firms indicated in the release.

Canada reports taxes revenues and consumer trends

The Canadian statistics agency issued an update on the financial results the country has seen by way of taxes since the opening of the recreational market on October 17, 2018.

Statistics Canada reported that the government has collected a total of C$186 million in taxes from legal cannabis products sold since the launch of adult-use sales up to the end of March.

In 2019 alone, provincial governments have accumulated C$79 million in excise taxes, while the federal government secured C$19 million of tax revenue.

The government agency also issued a new report on early trends from Canadian consumers, indicating a surprising increase in reported consumers during the first three months of 2019 in Ontario and Quebec. This study was conducted using self-reported data from Canadian consumers.

Market updates

Shoppers Drug Mart, a Loblaw Companies (TSX:L,OTC Pink:LBLCF) subsidiary, announced a new agreement on Monday (June 17) to use a blockchain-based program to track medical cannabis sold through its online platform.

The deal is being done in collaboration with TruTrace Technologies (CSE:TTT,OTC Pink:BKKSF) and will deploy  TruTrace’s StrainSecure technology. The Toronto-based company reached a listing on the Canadian Securities Exchange on June 14.

Ken Weisbrod, vice president of Shoppers Drug Mart, said it’s critical for medical cannabis consumers to know the source of their purchases so that both patients and practitioners can gain another level of certainty on the integrity of the product.

“When a patient takes medication, there is an expectation that it is standardized, and they can expect consistent clinical outcomes and results. Although that’s not always a guarantee within the medical cannabis industry at the moment, we’re hoping this new program can help change that,” the Shoppers executive said.

This past week, investors of multi-state operator Acreage Holdings (CSE:ACRG.U,OTCQX:ACRGF) and Canopy Growth (NYSE:CGC,TSX:WEED) voted their approval on the proposed acquisition arrangement between the two firms, which is set to take place once marijuana becomes federally legal in the US.

“Alongside our international market strategies and US Hemp strategy, we believe the acquisition of Acreage will be a key step in bolstering our position as a truly global company,” Bruce Linton, co-CEO of Canopy Growth, said in a press release.

Shares of Canopy Growth dropped on Friday (June 21) after the company issued its Q4 and fiscal 2019 results, reporting a net loss of just over C$323.3 million for the quarter. The net loss per share for the firm during Q4 was C$0.98, while its net loss per share for the full fiscal year was C$2.57.

As of 12:30 p.m. EDT on Friday, shares of the Canadian cannabis producer had taken hits both in New York, where they dropped 8.51 percent, and Toronto, with a decline of 8.18 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Editorial Disclosure: Acreage Holdings and TruTrace Technologies are clients of the Investing News Network. This article is not paid-for content.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less